Author

M. Heemskerk

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Chimeric HLA Antibody Receptor (CHAR) T Cells to Specifically Eliminate HLA-DQ-Specific B Cells.

BACKGROUND CAR T cell therapy has revolutionized the treatment of hematological malignancies by effectively eliminating tumor cells. In the field of kidney transplantation, comparable cellular therapies are being explored to facilitate transplantation and prevent graft rejection. Chimeric HLA antibody receptor (CHAR) T...

Carolt Arana, I. Gille, R. Hagedoorn et al. · Journal of the American Soci... · 0 citations

Aug 2026

Immunoglobulin constant domains as targets for T-cell receptor-based treatment of multiple myeloma.

Despite major progress with chimeric antigen receptor (CAR) T-cell therapy, multiple myeloma (MM) remains largely incurable, and most patient relapse. To broaden therapeutic options and overcome antigen escape, we explored T-cell receptor (TCR)-based targeting of intracellular antigens derived from immunoglobulin (Ig)...

M. Meeuwsen, A. Wouters, Johannes C. Wellershoff et al. · Blood · 0 citations

Open access Aug 2026

T-cell receptor repertoires against HLA class I-restricted minor histocompatibility antigens are highly diverse with a small subset of public clonotypes

Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) can be a curative treatment for hematological diseases. After HLA-matched alloHSCT, donor T cells may recognize minor histocompatibility antigens (MiHAs), which are polymorphic HLA-binding peptides on patient cells that are absent from donor cells...

K. Fuchs, M. van de Meent, M. Kester et al. · Journal for ImmunoTherapy of... · 0 citations